FYN inhibitors have been approved to treat various cancers (e.g., chronic myeloid leukemia and acute lymphoblastic leukemia)58,59 and tested in clinical trials for Alzheimer disease60–62. The gene discussed is FYN; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.